A novel 203 kD aberrant BCR‐ABL product in a girl with Philadelphia chromosome positive acute lymphoblastic leultaemia
Authors:
- 1 December 1993
- journal article
- case report
- Published by Wiley in British Journal of Haematology
- Vol. 85 (4) , 823-825
Abstract
Summary We report a girl with Ph1‐positive ALL with the aberrant BCR‐ABL product. In this case. bcr exon 3 jointed not to ordinal abl exon 2 but to exon 3 resulting in the production of a 20 3 kD BCR‐ABL fusion protein with marked tyrosine kinase activity. To our knowledge, this is the first report of an aberrant BCR‐ABL product in childhood. This case was characterized with younger age and low leucocyte count at the onset, but relapsed early like the typical Phl‐positive ALL, suggesting the diversity in the clinicopathogenesis of Ph1‐positive ALL.Keywords
This publication has 8 references indexed in Scilit:
- Immunological Classification of Childhood Acute Lymphoblastic LeukemiaPediatrics International, 1991
- BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent mannerCell, 1991
- Philadelphia chromosome positive childhood acute lymphoblastic leukemia: clinical and cytogenetic characteristics and treatment outcome. A Pediatric Oncology Group studyBlood, 1990
- Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene ProductsScience, 1990
- N‐terminal mutations activate the leukemogenic potential of the myristoylated form of c‐abl.The EMBO Journal, 1989
- Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemiaCell, 1987
- The chronic myelocytic cell line K562 contains a breakpoint in bcr and produces a chimeric bcr/c-abl transcript.Molecular and Cellular Biology, 1986
- Fused transcript of abl and bcr genes in chronic myelogenous leukaemiaNature, 1985